Looking at the Efficacy of SGLT2 Inhibitors in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

Due to the diverse etiologies and sub-phenotypes that characterize HFpEF (heart failure with preserved ejection fraction), it is challenging to treat all cases with a single medication [1,2]. As a result, patients with HFpEF and HFmrEF (Hear failure with mildly reduced ejection fraction defined as those with an EF of 40-49%) have few treatment alternatives. The current recommendations state that diuretics are suggested for HFpEF patients when needed to treat their symptoms [3,4]. The extensive range of pharmacotherapies that have been tried so far have not significantly improved the consequences for patients with HFmrEF or HFpEF. A crucial unmet need in the treatment of these individuals is the hunt for a pharmacotherapeutic drug that will reduce “hard endpoints,” such as mortality and serious cardiac events [5].